ATHN 7

Quality of Life in Emicizumab-treated People with Hemophilia A in the ATHN 7 Hemophilia Natural History Study – An Assessment of Baseline PROMIS®-29 Scores

Author(s):

Tyler W Buckner, Nabil Daoud, Lucy Lee, Jonathan Schwartz, Karina Raimundo, Michael Recht
Publication:
Blood
Date:
November 28, 2023
Topics:
hemophilia A, emicizumab, ATHN 7

Emicizumab prophylaxis in people with hemophilia A aged ≥50 years with comorbidities: experience from the ATHN 7 hemophilia natural history study

Author(s):

Tyler Buckner, Mike Recht, Lucy Lee, Paul Morton, Nabil Daoud
Publication:
ISTH 2023 Congress (poster)
Date:
June 24-28, 2023
Topics:
Hemophilia, comorbidities

Surgeries and procedures in people with haemophilia A on emicizumab prophylaxis, ATHN 7

Author(s):

Tyler Buckner, Shannon Carpenter, Nabil Daoud, Lucy Lee, Thomas McLean, Paul Morton, Michael Recht
Publication:
European Association for Haemophilia and Allied Disorders (EAHAD) Annual Meeting 2023
Date:
February 7-10, 2023
Topics:
Hemophilia, Treatments, Safety

Designing ATHN 7: Safety, effectiveness and practice of treatment of people with haemophilia in the United States through a natural history cohort study

Author(s):

Tyler W Buckner, Nabil Daoud, Moses Miles, Carrie O’Neill, Crystal Watson, Michael Recht
Publication:
The Journal of Haemophilia Practice
Date:
January 2, 2023
Topics:
ATHN 7, hemophilia treatment

Emicizumab and Females with Hemophilia A: Case Series from ATHN 7

Author(s):

Michael Recht, Nabil Daoud, Lucy Lee, Paul Morton, Leslie J Raffini
Publication:
Blood
Date:
November 15, 2022
Topics:
Emicizumab, females with hemophilia

Safety and Efficacy of Emicizumab in People with Hemophilia A Enrolled in the Hemophilia Natural History Study (ATHN 7)

Author(s):

Tyler Buckner, Shannon Carpenter, Christine Kempton, Lucy Lee, Lynn Malec, Thomas McLean, Paul Morton, Janice Staber, Michael Wang, Michael Recht
Publication:
ISTH 2022 Congress
Date:
July 9-13, 2022
Topics:
Safety, Efficacy, Emicizumab

Hemophilia Natural History Study (ATHN 7): Safety of Current Therapies for People with Hemophilia A or B

Author(s):

Tyler Buckner, Shannon L Carpenter, Nabil Daoud, Nikki Hirsh, Thomas W McLean, Carrie O’Neill, Leslie J Raffini, Ayesha Zia, Michael Recht
Publication:
Blood
Date:
November 5, 2021
Topics:
monitor, safety, new therapies, hemophilia A or B

Hemophilia Natural History Study (ATHN 7): Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia A and B

Author(s):

Tyler W Buckner, Shannon L Carpenter, Stacy E Croteau, Adam Cuker, Nabil Daoud, Christine L Kempton, Lynn M Malec, Thomas W McLean, Leslie Raffini, Janice M Staber, Michael Wang, Crystal Watson, Ayesha Zia, Michael Recht
Publication:
Blood
Date:
November 5, 2020
Topics:
new therapy, monitoring, HTCs

ATHN 7: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People with Hemophilia – Demographics and Preliminary Results

Author(s):

Tyler W Buckner, Nabdil Daoud, Stacy Croteau, Christine Kempton, Lynn Malec, Janice Staber, Michael Wang, Crystal Watson, Michael Recht
Publication:
ISTH 2020 Virtual Congress
Date:
July 12-14, 2020
Topics:
Safety, Cohort-Study, Hemophilia Therapies

Deaths Associated with Emicizumab in Patients with Hemophilia A

Author(s):

Louis M Aledort
Publication:
New England Journal of Medicine
Date:
February 20, 2020
Topics:
Death, Hemophilia, Emicizumab

Can’t find what you’re looking for?
Please contact support@athn.org for assistance.